TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.
TegoScience Inc (191420) - Net Assets
Latest net assets as of September 2025: ₩57.39 Billion KRW
Based on the latest financial reports, TegoScience Inc (191420) has net assets worth ₩57.39 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩82.18 Billion) and total liabilities (₩24.79 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩57.39 Billion |
| % of Total Assets | 69.83% |
| Annual Growth Rate | 7.87% |
| 5-Year Change | 1.78% |
| 10-Year Change | N/A |
| Growth Volatility | 14.02 |
TegoScience Inc - Net Assets Trend (2015–2024)
This chart illustrates how TegoScience Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for TegoScience Inc (2015–2024)
The table below shows the annual net assets of TegoScience Inc from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩49.86 Billion | +7.63% |
| 2023-12-31 | ₩46.33 Billion | -4.67% |
| 2022-12-31 | ₩48.60 Billion | +0.25% |
| 2021-12-31 | ₩48.47 Billion | -1.05% |
| 2020-12-31 | ₩48.99 Billion | +2.45% |
| 2019-12-31 | ₩47.82 Billion | +2.44% |
| 2018-12-31 | ₩46.68 Billion | +30.70% |
| 2017-12-31 | ₩35.71 Billion | +37.47% |
| 2016-12-31 | ₩25.98 Billion | +3.06% |
| 2015-12-31 | ₩25.21 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to TegoScience Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩8.06 Billion | 16.18% |
| Common Stock | ₩4.05 Billion | 8.13% |
| Other Components | ₩37.74 Billion | 75.69% |
| Total Equity | ₩49.86 Billion | 100.00% |
TegoScience Inc Competitors by Market Cap
The table below lists competitors of TegoScience Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Effecten-Spiegel AG
STU:EFS
|
$40.60 Million |
|
CB Industrial Product Holding
KLSE:7076
|
$40.60 Million |
|
Allcargo Logistics Limited
NSE:ALLCARGO
|
$40.62 Million |
|
ASTRO-MED INC. DL-01
F:AZO
|
$40.63 Million |
|
Thailand Prime Property Freehold and Leasehold Real Estate Investment Trust
BK:TPRIME
|
$40.59 Million |
|
Instabank ASA
OL:INSTA
|
$40.58 Million |
|
ESAF Small Finance Bank
NSE:ESAFSFB
|
$40.58 Million |
|
Emperor Energy Ltd
AU:EMP
|
$40.57 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in TegoScience Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 46,463,498,700 to 49,859,800,040, a change of 3,396,301,340 (7.3%).
- Net income of 3,349,660,810 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩3.35 Billion | +6.72% |
| Other Changes | ₩46.64 Million | +0.09% |
| Total Change | ₩- | 7.31% |
Book Value vs Market Value Analysis
This analysis compares TegoScience Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.08x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.69x to 2.08x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3508.18 | ₩12930.00 | x |
| 2017-12-31 | ₩4537.53 | ₩12930.00 | x |
| 2018-12-31 | ₩5781.08 | ₩12930.00 | x |
| 2019-12-31 | ₩5914.00 | ₩12930.00 | x |
| 2020-12-31 | ₩6092.89 | ₩12930.00 | x |
| 2021-12-31 | ₩6045.63 | ₩12930.00 | x |
| 2022-12-31 | ₩6069.56 | ₩12930.00 | x |
| 2023-12-31 | ₩5803.17 | ₩12930.00 | x |
| 2024-12-31 | ₩6227.36 | ₩12930.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently TegoScience Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.72%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 49.56%
- • Asset Turnover: 0.13x
- • Equity Multiplier: 1.05x
- Recent ROE (6.72%) is above the historical average (-0.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 5.84% | 19.67% | 0.29x | 1.02x | ₩-1.05 Billion |
| 2016 | 2.97% | 9.25% | 0.19x | 1.72x | ₩-1.83 Billion |
| 2017 | -16.86% | -69.67% | 0.18x | 1.33x | ₩-9.59 Billion |
| 2018 | -3.91% | -23.26% | 0.17x | 1.02x | ₩-6.49 Billion |
| 2019 | 1.79% | 13.48% | 0.13x | 1.02x | ₩-3.93 Billion |
| 2020 | 3.78% | 21.07% | 0.17x | 1.03x | ₩-3.05 Billion |
| 2021 | 0.29% | 1.68% | 0.16x | 1.05x | ₩-4.71 Billion |
| 2022 | 0.54% | 3.44% | 0.15x | 1.06x | ₩-4.60 Billion |
| 2023 | -5.00% | -29.88% | 0.16x | 1.05x | ₩-6.97 Billion |
| 2024 | 6.72% | 49.56% | 0.13x | 1.05x | ₩-1.64 Billion |
Industry Comparison
This section compares TegoScience Inc's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $96,196,506,488
- Average return on equity (ROE) among peers: -9.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| TegoScience Inc (191420) | ₩57.39 Billion | 5.84% | 0.43x | $40.59 Million |
| Sam Chun Dang Pharm. Co. Ltd (000250) | $114.32 Billion | 10.17% | 0.61x | $3.69 Billion |
| DongKoo Bio&Pharma Co. Ltd (006620) | $94.65 Billion | 9.66% | 0.53x | $57.77 Million |
| NatureCell Co.Ltd (007390) | $34.02 Billion | -9.48% | 0.55x | $37.82 Million |
| Sam-A Pharm. Co. Ltd (009300) | $148.92 Billion | 6.63% | 0.09x | $21.27 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $257.20 Billion | 4.73% | 0.21x | $50.06 Million |
| WooGene B&G Co. Ltd (018620) | $26.51 Billion | -25.02% | 1.26x | $10.61 Million |
| Oscotec Inc (039200) | $28.83 Billion | -91.10% | 0.70x | $890.75 Million |
| EstechPharma Co. Ltd (041910) | $123.30 Billion | 5.58% | 0.09x | $50.99 Million |
| Komipharm International Co. Ltd (041960) | $93.39 Billion | -15.32% | 0.50x | $237.27 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $40.83 Billion | 8.91% | 0.29x | $20.48 Million |